NRAS and melanoma: We next evaluated the effect of JQ‐1 (a prototype BET inhibitor) on cell viability and determined the half‐maximal inhibitory concentration (IC50) of JQ‐1 in NRAS‐mutant melanoma cells intrinsically resistant to MAPK inhibitors as well as non‐transformed cells (Fig 2A and Appendix Table S1).